#Pharmaceuticals #DrugPricing #HealthcarePolicy
www.cnbc.com
Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
Big pharma is grappling with the impact of new drug pricing deals with President Donald Trump and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.
#Healthcare #PharmacyServices #CommunityHealth
www.beckershospitalreview.com
New Research Shows Increased Urgency to Improve Community Pharmacy Access and Reduce Gaps in Service
VytlOne Releases 2nd Annual Healthcare Leader Report -- Reviving Access, Reclaiming Revenue: Strengthening Hospitals and Communities Through Strategic Pharmacy Expansion
AMARILLO, Texas, Nov.
#WeightManagement #ObesityTreatment #PharmaceuticalInnovation
www.nasdaq.com
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
Last month, Novo Nordisk NVO announced the FDA approval of the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction in the long term, and to reduce the risk of major adverse cardiovascular (CV) events.
#Hypertension #HeartHealth #Pharmaceuticals
www.benzinga.com
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterIdorsia receives approval from Health Canada for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.
#AI #Oncology #Pharmaceuticals
www.benzinga.com
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterInsilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development.
#Pharmaceuticals #ClinicalTrials #EndocrineDiseases
www.benzinga.com
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Crinetics Pharmaceuticals (NASDAQ:CRNX)
SAN DIEGO, Jan.
#Biotech #Pharmaceuticals #FDAApproval
seekingalpha.com
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug (NASDAQ:CORT)
CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.
#Healthcare #Pharmaceuticals #MarkCuban
www.benzinga.com
Why Was It Mark Cuban Who Took On Big Pharma? 'I'm Rich As F*** And I Didn't Care About The Money'
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Mark Cuban said that the reason he took on big pharma with his online pharmacy Cost Plus Drugs was that he could.
